Vertaling van "development programs for biosimilars " (Nederlands → Frans) :

R&D investments (+1.0 percentage points) were lower as productivity initiatives more than offset investments in development programs for biosimilars as well as other differentiated generics, including oncology injectables and respiratory products.
Les investissements en R&D (+1,0 point de pourcentage) ont diminué car les gains de productivité ont plus que compensé les investissements dans les programmes de développement de biosimilaires ainsi que d’autres génériques différenciés, comprenant les injectables en oncologie et les produits contre les maladies des voies respiratoires.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Significant investments were made in the first quarter of 2010 in R&D, including post-marketing commitments for A (H1N1) pandemic vaccines as well as the late-stage Menveo and MenB clinical development programs.
Au premier trimestre 2010, des investissements lourds ont été réalisés dans la R&D, comprenant des engagements ultérieurs à la vente pour les vaccins contre la pandémie de grippe A (H1N1) ainsi que des programmes de développement clinique ultime pour les vaccins Menveo et MenB.

Het loopt grotendeels in de derdewereldlanden zelf en wordt aangestuurd door wetenschappers ter plaatse. UNICEF, het UNDP (United Nations Development Program), de Wereldbank en de WHO sponsoren dit programma.
L’UNICEF, le UNDP (United Nations Development Program), la Banque Mondiale et l’Organisation mondiale de la Santé apportent leur soutien à ce programme.

Planned to initiate a Phase III clinical development program in chronic coronary heart disease in Q1 2011
Début d’un programme de développement clinique de phase III dans la maladie coronarienne chronique prévu

The savings were achieved even as Sandoz has continued to invest in the development of differentiated generics, such as biosimilars, oncological injectables and respiratory products.
Ces économies ont été dégagées quand bien même Sandoz a poursuivi ses investissements dans le développement de génériques différenciés, tels que des biosimilaires, des injectables en oncologie et des produits contre les maladies respiratoires.

R&D costs (7.5% of net sales) decreased slightly (+0.4 percentage points) as a percentage of sales as productivity savings funded the continued investments in the development of differentiated generics, such as biosimilar, oncological injectable and respiratory products.
Les coûts de R&D (7,5% du chiffre d’affaires net, +0,4 point de pourcentage) ont légèrement diminué en termes de pourcentage du chiffre d’affaires net, les gains de productivité ayant servi à financer les investissements continus dans le développement de génériques différenciés, tels que les biosimilaires, les injectables en oncologie et les produits respiratoires.

NEW YORK , N.Y., December 12 - Pfizer Inc. announced that Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) was introduced into the first childhood immunization program for pneumococcal disease (PD) in the developing world under the auspices of the Advance Market Commitment (AMC) when Nicaragua launched its program today .
NEW YORK , N.Y., December 12 - Pfizer Inc. announced that Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) was introduced into the first childhood immunization program for pneumococcal disease (PD) in the developing world under the auspices of the Advance Market Commitment (AMC) when Nicaragua launched its program today .

In developed countries, we also offer discounts and support programs to patients who lack medical insurance or cannot afford the treatment.
Dans les pays développés, nous proposons aussi des rabais et des programmes d’aide aux malades sans couverture d’assurance ou qui, pour des raisons financières, ne peuvent pas se faire soigner.

At Novartis, we put an absolute premium on ethical business conduct and fair dealing. Our credibility provides assurance for those who regulate and invest in our industry, helping us to finance the costs of pharmaceutical development and to run our corporate citizenship programs.
Chez Novartis, nous mettons tout en œuvre pour conduire nos affaires de manière éthique et loyale : la crédibilité et la fiabilité sont les valeurs maîtresses nous permettant de gagner la confiance des autorités réglementaires et des investisseurs, ce qui, en retour, nous aide à financer notre recherche pharmaceutique et à poursuivre notre engagement citoyen.